Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo. Beconi M, Aziz O, Matthews K, Moumné L, O’Connell C, et al., PLoS ONE 7(9): e44498. doi:10.1371/journal.pone.0044498 (2012)
OPEN ACCES, FULL TEXT PDF
Keywords: Histone deacetylase (HDAC) inhibitors, neurological disorders, pimelic diphenylamide HDAC inhibitors, Friedreich’s ataxia, Huntington’s disease.
Subscribe to:
Posts (Atom)
